BR0309809A - indução de toleráncia imunológica especìfica quanto ao antìgeno - Google Patents
indução de toleráncia imunológica especìfica quanto ao antìgenoInfo
- Publication number
- BR0309809A BR0309809A BRPI0309809-5A BR0309809A BR0309809A BR 0309809 A BR0309809 A BR 0309809A BR 0309809 A BR0309809 A BR 0309809A BR 0309809 A BR0309809 A BR 0309809A
- Authority
- BR
- Brazil
- Prior art keywords
- toleragen
- antigen
- induction
- immunological tolerance
- specific immune
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 230000001900 immune effect Effects 0.000 title abstract 2
- 230000006698 induction Effects 0.000 title abstract 2
- 230000006058 immune tolerance Effects 0.000 abstract 2
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
"INDUçãO DE TOLERáNCIA IMUNOLóGICA ESPECìFICA QUANTO AO ANTìGENO". Tolerância imune específica quanto ao antígeno é induzida em um hospedeiro mamífero por administração de um tolerágeno em combinação com um regime de imunossupressão. Os métodos opcionalmente incluem um período de condicionamento precedente, em que agentes imunossupressores são administrados na ausência do tolerágeno. Depois do regime tolerizantes, o hospedeiro é retirado dos agentes supressores, mas é capaz de manter tolerância imune específica com relação aos epítopos imunogênicos presentes no tolerágeno. Opcionalmente, o tolerágeno terá propriedades de elevada assimilação, que permitem assimilação in vivo em baixas concentrações, em uma ampla variedade de tipos de células tolerizantes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/141,668 US7485314B2 (en) | 2002-05-06 | 2002-05-06 | Induction of antigen specific immunologic tolerance |
PCT/US2003/013843 WO2003094840A2 (en) | 2002-05-06 | 2003-05-05 | Induction of antigen specific immunologic tolerance |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0309809A true BR0309809A (pt) | 2007-01-09 |
Family
ID=29399718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0309809-5A BR0309809A (pt) | 2002-05-06 | 2003-05-05 | indução de toleráncia imunológica especìfica quanto ao antìgeno |
Country Status (16)
Country | Link |
---|---|
US (3) | US7485314B2 (pt) |
EP (1) | EP1507555B1 (pt) |
JP (1) | JP4933042B2 (pt) |
CN (1) | CN100360182C (pt) |
AR (1) | AR039882A1 (pt) |
AU (1) | AU2003228829B2 (pt) |
BR (1) | BR0309809A (pt) |
CA (1) | CA2492394A1 (pt) |
ES (1) | ES2401681T3 (pt) |
HK (1) | HK1081438A1 (pt) |
IL (1) | IL165016A (pt) |
MX (1) | MXPA04009292A (pt) |
TW (1) | TWI349556B (pt) |
UY (1) | UY27795A1 (pt) |
WO (1) | WO2003094840A2 (pt) |
ZA (1) | ZA200409787B (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
WO2003020039A1 (en) * | 2001-08-28 | 2003-03-13 | Rush-Presbyterian-St. Luke's Medical Center | Immune tolerance to predetermined antigens |
KR101086533B1 (ko) * | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | 중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물 |
WO2005002515A2 (en) | 2003-06-20 | 2005-01-13 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
ATE514783T1 (de) | 2003-11-12 | 2011-07-15 | Schering Corp | Plasmidsystem zur expression mehrerer gene |
TW200526684A (en) * | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
JP2008521907A (ja) * | 2004-12-03 | 2008-06-26 | シェーリング コーポレイション | 抗igf1r治療について患者を予め選択するためのバイオマーカー |
AU2006209837A1 (en) * | 2005-02-04 | 2006-08-10 | Dow Agrosciences, Llc | Anti-T cell and autoantigen treatment of autoimmune disease |
AU2006236637B2 (en) * | 2005-04-15 | 2012-09-06 | Merck Sharp & Dohme Corp. | Methods and compositions for treating or preventing cancer |
CN101287761A (zh) * | 2005-06-15 | 2008-10-15 | 先灵公司 | 抗-igf1r抗体制剂 |
JP2009508494A (ja) | 2005-09-16 | 2009-03-05 | ラプトール ファーマシューティカル インコーポレイテッド | Crを含むタンパク質に対して特異的な受容体−結合タンパク質(rap)変異体を含む組成物およびその使用 |
WO2008125903A2 (en) * | 2006-12-12 | 2008-10-23 | Chaim Sheba Medical Center | Method of inhibiting an undesired immune response |
JP2010524849A (ja) * | 2007-03-21 | 2010-07-22 | ラプトール ファーマシューティカル インコーポレイテッド | 環状受容体関連蛋白ペプチド |
HUE034850T2 (en) | 2008-05-07 | 2018-03-28 | Biomarin Pharm Inc | Lysosomal targeting peptides and their use |
EP2475376B1 (en) | 2009-06-17 | 2016-03-30 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
EP2493487B1 (en) * | 2009-10-27 | 2016-08-24 | Erytech Pharma | Composition to induce specific immune tolerance |
PT2632479T (pt) * | 2010-10-27 | 2017-07-24 | Baxalta Inc | Péptidos de fviii para indução de tolerância imunitária e imunodiagnóstico |
CA2834532A1 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses |
CA2835819A1 (en) * | 2011-05-16 | 2012-11-22 | Genzyme Corporation | Induction of immune tolerance using methotrexate |
EA029560B1 (ru) | 2012-01-12 | 2018-04-30 | Байоджен Эмэй Инк. | Применение химерного фактора свертывания крови для уменьшения ингибирующего иммунного ответа у субъекта |
JP2015511628A (ja) * | 2012-04-02 | 2015-04-20 | ユニバーシティ オブ ブリストル | 寛容化誘導組成物 |
CN106668852B (zh) * | 2012-04-13 | 2020-12-25 | 艾棣维欣(苏州)生物制药有限公司 | 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用 |
LT3115372T (lt) | 2012-11-27 | 2019-06-25 | Biomarin Pharmaceutical Inc. | Tiksliniai terapiniai lizosominio fermento sulieti baltymai ir jų panaudojimas |
KR20220025908A (ko) | 2013-05-03 | 2022-03-03 | 셀렉타 바이오사이언시즈, 인크. | 제i형 및 제iv형 과민성을 감소시키기 위한 관용유발 합성 나노담체의 국부, 병용 투여 |
KR20240093939A (ko) * | 2013-05-15 | 2024-06-24 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달 |
EP3189147A1 (en) | 2014-09-07 | 2017-07-12 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
EP3344575B1 (en) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
WO2017079729A1 (en) | 2015-11-06 | 2017-05-11 | Biomarin Pharmaceutical Inc. | Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes |
BR112018071156A2 (pt) | 2016-04-15 | 2019-03-12 | The Trustees Of The University Of Pennsylvania | terapia de gene para tratar mucopolissacaridose tipo ii |
CA3055936A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
EP3684938A1 (en) | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
JPWO2019245038A1 (ja) * | 2018-06-22 | 2021-07-08 | 株式会社Junten Bio | 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法 |
CN113301925A (zh) | 2018-12-19 | 2021-08-24 | 小利兰·斯坦福大学理事会 | 用于溶酶体靶向的双官能分子以及相关的组合物和方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4117118A (en) | 1976-04-09 | 1978-09-26 | Sandoz Ltd. | Organic compounds |
US5135915A (en) * | 1988-10-14 | 1992-08-04 | Genentech, Inc. | Method for the treatment of grafts prior to transplantation using TGF-.beta. |
DK0572478T3 (da) | 1991-02-22 | 2006-01-16 | Inst Medical W & E Hall | HBGAD- og HIGAD-polypeptider og nukleinsyre og anvendelse heraf til diagnostik og behandling af GAD-autoantigen-associerede sygdomme |
US6149909A (en) | 1995-06-23 | 2000-11-21 | Women's And Children's Hospital | Synthetic α-L-iduronidase and genetic sequences encoding same |
CA2129351A1 (en) * | 1992-02-10 | 1993-08-19 | Barton F. Haynes | Use of synthetic peptides to induce tolerance to pathogenic t and b cell epitopes of autoantigens |
US5747034A (en) | 1992-07-09 | 1998-05-05 | Chiron Corporation | Methods and materials for the induction of T cell anergy |
US5597563A (en) * | 1992-09-04 | 1997-01-28 | Beschorner; William E. | Method induction of antigen-specific immune tolerance |
WO1996023882A1 (en) * | 1995-01-31 | 1996-08-08 | The Rockefeller University | IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF |
JP2001511187A (ja) | 1997-02-28 | 2001-08-07 | エンゾー セラピュウティクス, インコーポレイテッド | 選択的免疫ダウンレギュレーション(sidr)を行う新規プロセス |
US6426208B1 (en) * | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
US20020014242A1 (en) * | 2000-07-31 | 2002-02-07 | Abraham Scaria | Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
US20050191309A1 (en) * | 2002-05-06 | 2005-09-01 | Kakkis Emil D. | Induction of antigen specific immunologic tolerance |
-
2002
- 2002-05-06 US US10/141,668 patent/US7485314B2/en not_active Expired - Fee Related
-
2003
- 2003-05-05 US US10/429,314 patent/US20040009906A1/en not_active Abandoned
- 2003-05-05 CA CA002492394A patent/CA2492394A1/en not_active Abandoned
- 2003-05-05 BR BRPI0309809-5A patent/BR0309809A/pt not_active IP Right Cessation
- 2003-05-05 CN CNB038104040A patent/CN100360182C/zh not_active Expired - Fee Related
- 2003-05-05 AU AU2003228829A patent/AU2003228829B2/en not_active Ceased
- 2003-05-05 JP JP2004502929A patent/JP4933042B2/ja not_active Expired - Fee Related
- 2003-05-05 WO PCT/US2003/013843 patent/WO2003094840A2/en active Application Filing
- 2003-05-05 ES ES03726601T patent/ES2401681T3/es not_active Expired - Lifetime
- 2003-05-05 EP EP03726601A patent/EP1507555B1/en not_active Expired - Lifetime
- 2003-05-05 MX MXPA04009292A patent/MXPA04009292A/es active IP Right Grant
- 2003-05-06 TW TW092112346A patent/TWI349556B/zh not_active IP Right Cessation
- 2003-05-06 AR ARP030101591A patent/AR039882A1/es unknown
- 2003-05-06 UY UY27795A patent/UY27795A1/es not_active Application Discontinuation
-
2004
- 2004-11-03 IL IL165016A patent/IL165016A/en not_active IP Right Cessation
- 2004-12-02 ZA ZA200409787A patent/ZA200409787B/en unknown
-
2006
- 2006-02-07 HK HK06101602A patent/HK1081438A1/xx not_active IP Right Cessation
-
2009
- 2009-03-27 US US12/412,986 patent/US7883707B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AR039882A1 (es) | 2005-03-09 |
US20030211113A1 (en) | 2003-11-13 |
HK1081438A1 (en) | 2006-05-19 |
AU2003228829A1 (en) | 2003-11-11 |
EP1507555B1 (en) | 2012-12-19 |
TW200400045A (en) | 2004-01-01 |
US7485314B2 (en) | 2009-02-03 |
CA2492394A1 (en) | 2003-11-20 |
CN100360182C (zh) | 2008-01-09 |
ZA200409787B (en) | 2006-07-26 |
JP2005530762A (ja) | 2005-10-13 |
IL165016A0 (en) | 2005-12-18 |
US20090238818A1 (en) | 2009-09-24 |
ES2401681T3 (es) | 2013-04-23 |
JP4933042B2 (ja) | 2012-05-16 |
EP1507555A4 (en) | 2009-07-15 |
MXPA04009292A (es) | 2005-06-08 |
WO2003094840A2 (en) | 2003-11-20 |
US7883707B2 (en) | 2011-02-08 |
IL165016A (en) | 2012-01-31 |
EP1507555A2 (en) | 2005-02-23 |
AU2003228829B2 (en) | 2009-05-21 |
UY27795A1 (es) | 2003-11-28 |
TWI349556B (en) | 2011-10-01 |
US20040009906A1 (en) | 2004-01-15 |
WO2003094840A3 (en) | 2004-03-11 |
CN1652814A (zh) | 2005-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0309809A (pt) | indução de toleráncia imunológica especìfica quanto ao antìgeno | |
CY1123299T1 (el) | Ανοσοενισχυτικη μηνιγκιτιδοκοκκικη πρωτεϊνη προσδεσης παραγοντα η | |
BR0014386A (pt) | Composição | |
BR9708387A (pt) | Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada. | |
BR0207067A (pt) | Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo | |
BR112013021871A2 (pt) | lentes de contato de silicone hidrogel com níveis aceitáveis de perda de energia | |
BR0208207A (pt) | Redução da imunogenicidade das proteìnas de fusão | |
BR0109158A (pt) | Cepa alterada do vìrus de varìola bovina de ankara (mva) | |
BR0207854A (pt) | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido | |
Gonzalez et al. | Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review | |
BR9106374A (pt) | Vacina oral e processo de extrair uma imunoresponsta em um mamifero | |
BR0108386C1 (pt) | urato oxidase purificada (uricase), conjugado de uricase, composição farmacêutica para reduzir os nìveis de ácido úrico nos fluidos ou tecidos corporais, método para a purificação de uricase dotada de imunogenicidade reduzida | |
WO2004091543A3 (en) | Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells | |
ATE309378T1 (de) | Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung | |
BR9908424A (pt) | Processo para purificar uma preparação de herpesvìrus | |
Forsum et al. | Distribution of Ia‐antigen‐like molecules on non‐lymphoid tissues | |
BR0312474A (pt) | Partìcula viral adjuvante | |
Jahanian et al. | Marginal deficiencies of dietary arginine and methionine could suppress growth performance and immunological responses in broiler chickens | |
BR0309963A (pt) | Proteìna de fusão das proteìnas reguladoras/acessórias do hiv | |
BR0113213A (pt) | Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo | |
BR0215588A (pt) | Compostos imunoefetores | |
WO2006052668A3 (en) | Induction of antigen specific immunologic tolerance | |
TR200100948T2 (tr) | Cinsel yoldan bulaşan hastalıklara karşı aşı | |
BR0008645A (pt) | Métodos de induzir uma resposta imunológica contra um imunógeno em um indivìduo, de reduzir rejeição de células, tecido ou órgão doadores nã0-assemelhados em um indivìduo e uma resposta imunológica dominante em um indivìduo e de expandir uma subpopulação de células t associadas com uma resposta imunológica especìfica, plasmìdeo, e, composição | |
BR112023002724A2 (pt) | Neoantígenos ras e seus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE REIVINDICADA (US10/141,668) POR NAO ATENDER A DISPOSICAO PREVISTA NO ART.16 6O E 7O DA LPI. |
|
B150 | Others concerning applications: publication cancelled [chapter 15.30 patent gazette] |
Free format text: ANULADA A PERDA DE PRIORIDADE(15.9) PUBLICADA NA RPI 2011 POR TER SIDO INDEVIDA. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |